Mandate

Vinge advises on division of Creades

January 24, 2013

On the initiative of the majority shareholders, Bioinvestor and Pan Capital, it is proposed that Creades (NASDAQ OMX First North) will be divided into two companies pursuant to a squeeze out procedure whereby 30 per cent of Creades’ net worth will be transferred to a new, unlisted company, Sedarec, which will be distributed to the shareholders in the manner desired by them. Pan Capital will become the majority shareholder in Sedarec which, following completion of the squeeze out procedure, will be liquidated under Pan Capital’s management, whereas Creades, with Bioinvestor as its majority shareholder, will continue its long-term strategy.

Vinge team advising Creades primarily consisted of partner Erik Sjöman and associate Jo-Anna Nordström.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024